Results 71 to 80 of about 41,661 (291)

Metabolic effects of androgen deprivation therapy

Korean Journal of Urology, 2015
The therapeutic effects and side effects of androgen deprivation therapy (ADT), which is a main treatment method for metastatic prostate cancer, are well known, but the metabolic effects have only recently been studied. This review describes the effects of ADT on body habitus, insulin resistance, lipid profiles, diabetes, metabolic syndrome, and ...
Choi, See Min, Kam, Sung Chul
openaire   +2 more sources

Heat Shock Protein 90: From Molecular Chaperone Function to Therapeutic Targeting in Malignancies

Advanced Science, EarlyView.
In this review, an integrated conceptual framework linking HSP90's molecular chaperone functions to its pathological roles in cancer is proposed. HSP90 serves as a central node that integrates oncogenic signaling, buffers proteotoxic stress, maintains cancer stem cell plasticity, and shapes tumor‐immune interactions, all of which converge to drive ...
Beibei Zhang, Xinxin Zou, Jiansong Zhou, Qinmiao Sun, Dahua Chen   +4 more
wiley   +1 more source

Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation?

BMC Cancer, 2012
Background There has been substantial increase in use of androgen deprivation therapy as adjuvant management of prostate cancer. However, this leads to a range of musculoskeletal toxicities including reduced bone mass and increased skeletal fractures ...
Newton Robert U, Taaffe Dennis R, Spry Nigel, Cormie Prue, Chambers Suzanne K, Gardiner Robert A, Shum David HK, Joseph David, Galvão Daniel A   +8 more
doaj   +1 more source

Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy. [PDF]

PLoS ONE, 2013
Cancer cell metabolism responsive to androgen deprivation therapy (ADT) may be involved in the development and progression of prostate cancer and the ultimate failure of androgen-deprivation therapy.
Lei Yan, Zhaoquan Xing, Zhaoxin Guo, Zhiqing Fang, Wei Jiao, Xiaoyu Guo, Zhonghua Xu, Zhenghui Fang, Anders Holmberg, Sten Nilsson, Zhaoxu Liu   +10 more
doaj   +1 more source

CCT2 Promotes Prostate Cancer Progression Through EIF3F‐Dependent Stabilization of FASN

Advanced Science, EarlyView.
ABSTRACT Prostate cancer (PCa) is increasingly recognized to be driven by dysregulated lipid metabolism. Although fatty acid synthase (FASN) is highly expressed in PCa, the mechanisms governing FASN protein stability and its functional integration into oncogenic lipid metabolism remain poorly defined.
Shun Xu, Yifan Zhang, Haolin Li, Shengyu Zhao, Xiaoran Dai, Qili Xu, Mintian Fei, Chun Li, Zhihui Zou, Baojun Wang, Li Zhang, Hui Wang, Ligang Zhang, Chaozhao Liang   +13 more
wiley   +1 more source

Comparing the safety and efficacy of systemic therapies for high-risk biochemically recurrent hormone-sensitive prostate cancer: a network meta-analysis

Frontiers in Oncology
IntroductionEnzalutamide is the only androgen receptor pathway inhibitor approved by the United States Food and Drug Administration and the European Medicines Agency to treat high-risk biochemically recurrent non-metastatic hormone-sensitive prostate ...
Armen Aprikian, Andrew Chilelli, Thomas McLean, Anchen Nasr, Arijit Ganguli, Alexis Serikoff, Franco Guzman, Ifigeneia Barouma, Maria Zacharioudaki, Stephen J. Freedland, Stephen J. Freedland   +10 more
doaj   +1 more source

Endocrine manipulations in cancer prostate: A review

Indian Journal of Endocrinology and Metabolism, 2012
Prostate cancer is an androgen dependent condition where Dihydrotestosterone promotes the growth of the neoplastic tissue. Androgen deprivation has been the mainstay of therapy for this condition. This can be achieved by surgical or medical means.
Rajesh Rajput, Ashish Sehgal
doaj   +1 more source

Androgen deprivation therapy and cardiovascular complications

Bratislava Medical Journal, 2017
Cardiovascular complications associated with the use of antiandrogens have already been known for some time. Based on the results of the latest meta-analyses and clinical studies published in the last few years, the attention of the scientific community is focused on the deleterious cardiovascular effects of gonadotropine-releasing hormon agonists in ...
Z, Poljak, I, Hulin, L, Maruscakova, A, Carter, B, Mladosievicova   +4 more
openaire   +3 more sources

Cholesterol‐Mediated Metabolic‐mechanotransductive Crosstalk Orchestrates Castration Resistance in Prostate Cancer

Advanced Science, EarlyView.
Full androgen deprivation (FAD) induces paracrine cholesterol in prostate cancer that drives the polarization of cancer‐associated fibroblasts (CAFs) and subsequent elevated matrix stiffness. Matrix stiffness in turn potentiates tumor cell survival under FAD pressure via dual mechanotransductive activation of the IRE1α‐XBP1s stress‐response axis ...
Shaojie Liu, Chao Xu, Jun Jiang, Limin He, Yike Zhou, Zhengxuan Li, Yu Li, Keying Zhang, Fa Yang, Tong Lu, Hongtao Song, Hai Zhu, Zhihao Hu, Xiaolong Zhao, Kai Gan, Hongji Li, Bo Yang, Rui Zhang, Weihong Wen, Donghui Han, Weijun Qin   +20 more
wiley   +1 more source

Targeting the HSPA8‐CMA‐ATP6V1A Axis Triggers Lysosomal Hyperacidification and Catastrophic Vacuolation in Prostate Cancer

Advanced Science, EarlyView.
Our experimental evidence supports a model in which ALO targets the HSPA8‐CMA‐ATP6V1A axis to induce lysosomal hyperacidification and initiate osmotic and lipidomic stress. These changes are associated with LMP and loss of lysosomal integrity in prostate cancer cells.
Bingzheng An, Ze Gao, Shuo Chen, Liwei Meng, Chen Zhang, Kefan Song, Haochen Cui, Lei Yan, Zhiqing Fang   +8 more
wiley   +1 more source